"Oligopeptides" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Peptides composed of between two and twelve amino acids.
Descriptor ID |
D009842
|
MeSH Number(s) |
D12.644.456
|
Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Oligopeptides".
Below are MeSH descriptors whose meaning is more specific than "Oligopeptides".
This graph shows the total number of publications written about "Oligopeptides" by people in this website by year, and whether "Oligopeptides" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
Year | Major Topic | Minor Topic | Total |
---|
1994 | 1 | 6 | 7 |
1995 | 1 | 3 | 4 |
1996 | 2 | 1 | 3 |
1997 | 3 | 5 | 8 |
1998 | 5 | 2 | 7 |
1999 | 2 | 3 | 5 |
2000 | 2 | 1 | 3 |
2001 | 0 | 7 | 7 |
2002 | 7 | 2 | 9 |
2003 | 5 | 2 | 7 |
2004 | 2 | 8 | 10 |
2005 | 9 | 9 | 18 |
2006 | 6 | 7 | 13 |
2007 | 3 | 4 | 7 |
2008 | 7 | 2 | 9 |
2009 | 7 | 6 | 13 |
2010 | 8 | 3 | 11 |
2011 | 10 | 8 | 18 |
2012 | 8 | 5 | 13 |
2013 | 5 | 15 | 20 |
2014 | 7 | 4 | 11 |
2015 | 2 | 9 | 11 |
2016 | 3 | 2 | 5 |
2017 | 3 | 1 | 4 |
2018 | 3 | 3 | 6 |
2019 | 4 | 5 | 9 |
2020 | 6 | 3 | 9 |
2021 | 6 | 4 | 10 |
2022 | 0 | 3 | 3 |
2023 | 0 | 2 | 2 |
2024 | 0 | 1 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Oligopeptides" by people in Profiles.
-
Chimeric oncolytic adenovirus evades neutralizing antibodies from human patients and exhibits enhanced anti-glioma efficacy in immunized mice. Mol Ther. 2024 Mar 06; 32(3):722-733.
-
Oncolytic virotherapy for the treatment of pediatric brainstem gliomas. Rev Neurol (Paris). 2023 Jun; 179(5):475-480.
-
Tisotumab vedotin in recurrent or metastatic cervical cancer. Curr Probl Cancer. 2023 06; 47(3):100952.
-
KRD vs. VRD as induction before autologous hematopoietic progenitor cell transplantation for high-risk multiple myeloma. Bone Marrow Transplant. 2022 07; 57(7):1142-1149.
-
Convection Enhanced Delivery of the Oncolytic Adenovirus Delta24-RGD in Patients with Recurrent GBM: A Phase I Clinical Trial Including Correlative Studies. Clin Cancer Res. 2022 04 14; 28(8):1572-1585.
-
Mitigation and management strategies for ocular events associated with tisotumab vedotin. Gynecol Oncol. 2022 05; 165(2):385-392.
-
RAR? activation sensitizes human myeloma cells to carfilzomib treatment through the OAS-RNase L innate immune pathway. Blood. 2022 01 06; 139(1):59-72.
-
A phase I study of the WT2725 dosing emulsion in patients with advanced malignancies. Sci Rep. 2021 11 16; 11(1):22355.
-
An immune-competent, replication-permissive Syrian Hamster glioma model for evaluating Delta-24-RGD oncolytic adenovirus. Neuro Oncol. 2021 11 02; 23(11):1911-1921.
-
Phase 1 trial of carfilzomib in relapsed/refractory peripheral T-cell lymphoma. Ann Hematol. 2022 Feb; 101(2):335-340.